A phase I, first-in-human dose-escalation and triple-negative breast cancer dose-expansion study of a TROP2-ADC F0024 (FDA018). Du Y, Meng Y, Liu X, Wang J, et al. Eur J Cancer 2026;248:117063.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Du Y, Meng Y, Liu X, Wang J, et al. A phase I, first-in-human dose-escalation and triple-negative breast cancer dose-expansion study of a TROP2-ADC F0024 (FDA018). Eur J Cancer 2026;248:117063.
PMID: 42810148